A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

NCT05367700 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

CML, Chronic Phase
CML, Accelerated Phase

Interventions

DRUG: HS-10382(Part 1: Dose escalation)
DRUG: HS-10382(Part 2: Dose expansion)

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.